TROPION-PanTumor03:高缓解安全佳,Dato-DXd为复发性妇瘤带来新选择 TROPION-PanTumor03研究是一项多中心、开放标签的II期试验,评估了Dato-DXd作为单药治疗和与其他药物联用在多种肿瘤中的疗效与安全性。本次会议报告了子宫内膜癌和...
TROPION-PanTumor03研究是一项多中心、开放标签的II期试验,评估了Dato-DXd作为单药治疗和与其他药物联用在多种肿瘤中的疗效与安全性。本次会议报告了子宫内膜癌和卵巢癌队列接受Dato-DXd单药治疗的研究结果,研究设计如下(图1)2。 图1. TROPION-PanTumor03研究子宫内膜癌和卵巢癌队列设计 结果显示,截至数据截止日...
Methods: The phase 2, multicenter, open-label TROPION-PanTumor03 study (NCT05489211) is exploring safety and efficacy of Dato-DXd as monotherapy and in combination with various anticancer agents (e.g. durvalumab, AZD5305, nivolumab, bevacizumab, chemotherapies) that may be active in the tumor...
Abstract P6-10-03: Datopotamab Deruxtecan (Dato-DXd) in Advanced Triple-Negative Breast Cancer (TNBC): Updated Results From the Phase 1 TROPION-PanTumor01 ... Background: Datopotamab deruxtecan (Dato-DXd) is an antibody-drug conjugate (ADC) consisting of a humanized anti-TROP2 IgG1...